AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 12 min read$DRTS

Levy Raphi sold $240K of DRTS

Levy Raphi (Chief Financial Officer) sold 20,000 shares of Alpha Tau Medical Ltd. (DRTS) at $12.00 ($0.24M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Levy Raphi
Published Jul 1, 2026, 12:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 1:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DRTS
Neutral
medium confidence
Mentioned
$DRTS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DRTSNeutralLow
01

Why it matters

The filing discloses an officer’s open-market sale of 20,000 shares at a stated price, but it does not include new business developments.

02

Market read

Traders may briefly reassess near-term sentiment around insider behavior, but the 10b5-1 structure reduces interpretive weight.

03

What to watch

Look for whether the sale is part of a larger, multi-tranche 10b5-1 program and compare with prior insider activity; one Form 4 alone is often not predictive.

Relevance 3/10Novelty 4/10Timing: today’s SEC Form 4 filing (filed 2026-07-01)

Background

The article is a primary-source SEC Form 4 insider transaction for Alpha Tau Medical Ltd. (DRTS).

Company-level read

Ticker impact

$DRTSNeutralMedium confidence
Context

CFO Levy Raphi filed a Form 4 selling 20,000 shares of DRTS at $12.0022/share on 2026-06-30 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The disclosure is a scheduled open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or operational change.

Market effects

Sector

Minimal; this is company-specific insider transaction data with no sector-wide read-across.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely liquidity-driven; traders may ignore it unless paired with other negative signals (missed guidance, financing needs, or repeated heavy selling).

Key entities

  • issuer
    DRTS

    Alpha Tau Medical Ltd., the company whose insider transaction was reported.

  • insider
    Levy Raphi

    Chief Financial Officer who sold shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Related articles

JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min